title: European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
abstract: BACKGROUND
  Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations.
  
  
  METHODS
  A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated.
  
  
  RESULTS
  The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used.
  
  
  CONCLUSIONS
  These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Paris, France Department of rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France.
authors.forename: L
authors.identifier: http://orcid.org/0000-0002-4528-310X
authors.initials: L
authors.lastname: Gossec
authors.affiliation: Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria Second Department of Medicine, Hietzing Hospital, Vienna, Austria.
authors.forename: J S
authors.identifier: http://orcid.org/0000-0002-8899-9087
authors.initials: JS
authors.lastname: Smolen
authors.affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.
authors.forename: S
authors.identifier: http://orcid.org/0000-0002-8899-9087
authors.initials: S
authors.lastname: Ramiro
authors.affiliation: EULAR, representing People with Arthritis/Rheumatism in Europe (PARE), London, UK.
authors.forename: M
authors.initials: M
authors.lastname: de Wit
authors.affiliation: Research Laboratory and Clinical Division of Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Cutolo
authors.affiliation: Medicine Faculty, Paris Descartes University, Paris, France Rheumatology B Department, APHP, Cochin Hospital, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.affiliation: Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
authors.forename: P
authors.initials: P
authors.lastname: Emery
authors.affiliation: Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands Atrium Medical Center, Heerlen, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Landewé
authors.affiliation: North Devon, UK.
authors.forename: S
authors.initials: S
authors.lastname: Oliver
authors.affiliation: Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
authors.forename: D
authors.initials: D
authors.lastname: Aletaha
authors.affiliation: EULAR, representing People with Arthritis/Rheumatism in Europe (PARE), London, UK.
authors.forename: N
authors.initials: N
authors.lastname: Betteridge
authors.affiliation: Rheumazentrum Ruhrgebiet, Herne and Ruhr-Universität Bochum, Herne, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Braun
authors.affiliation: Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Burmester
authors.affiliation: Arthritis Unit, Department of Rheumatology, Hospital Clínic and IDIBAPS, Barcelona, Spain.
authors.forename: J D
authors.initials: JD
authors.lastname: Cañete
authors.affiliation: Belgrade University School of Medicine, Belgrade, Serbia.
authors.forename: N
authors.initials: N
authors.lastname: Damjanov
authors.affiliation: Department of Rheumatology, St. Vincent's University Hospital and Conway Institute, University College Dublin, Dublin, Ireland.
authors.forename: O
authors.initials: O
authors.lastname: FitzGerald
authors.affiliation: Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden Sweden and School of Business, Engineering and Science, Halmstad University, Halmstad, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Haglund
authors.affiliation: Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.
authors.forename: P
authors.initials: P
authors.lastname: Helliwell
authors.affiliation: Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
authors.forename: T K
authors.initials: TK
authors.lastname: Kvien
authors.affiliation: Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium.
authors.forename: R
authors.initials: R
authors.lastname: Lories
authors.affiliation: Department of Dermatology, University Hospital Münster, Münster, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Luger
authors.affiliation: A.DI.PSO. (Associazione per la Difesa degli Psoriasici)-PE.Pso.POF (Pan European Psoriasis Patients' Organization Forum), Rome, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Maccarone
authors.affiliation: Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
authors.forename: H
authors.initials: H
authors.lastname: Marzo-Ortega
authors.affiliation: Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
authors.forename: D
authors.initials: D
authors.lastname: McGonagle
authors.affiliation: Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
authors.forename: I B
authors.initials: IB
authors.lastname: McInnes
authors.affiliation: Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Olivieri
authors.affiliation: Institute and Clinic of Rheumatology Charles University Prague, Czech Republic.
authors.forename: K
authors.initials: K
authors.lastname: Pavelka
authors.affiliation: Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Schett
authors.affiliation: Department of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Sieper
authors.affiliation: Ghent University Hospital, Ghent, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: van den Bosch
authors.affiliation: Centre for Arthritis and Rheumatic Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland.
authors.forename: D J
authors.initials: DJ
authors.lastname: Veale
authors.affiliation: Schoen Klinik Hamburg, Rheumatology and Clinical Immunology, Hamburg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Wollenhaupt
authors.affiliation: Department of Rheumatology and Clinical Immunology, German Rheumatism Research Centre Berlin, Charité-University Medicine Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Zink
authors.affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.
authors.forename: D
authors.identifier: http://orcid.org/0000-0002-5781-158X
authors.initials: D
authors.lastname: van der Heijde
mesh_terms: D000465:Algorithms; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D019468:Disease Management; D005060:Europe; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D012219:Rheumatology; D012955:Societies, Medical
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D005938:Glucocorticoids
keywords: DMARDs (biologic); DMARDs (synthetic); Psoriatic Arthritis